GlassScriptPhysician profile
Allison S Brewer-Reed
NPI 1427038983
$9,950.25
in general payments reported to CMS, 2019-2025
45 companies · $899 in 2025
The $899 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,931 · 2022: $2,147 · 2023: $1,847 · 2024: $2,125 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,865 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,865.33 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,756.77 | 2021-2025 | |
| Pfizer INC. | $930.95 | 2021-2025 | |
| Lilly USA, LLC | $915.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $816.01 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $561.55 | 2021-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.96 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $439.75 | 2021-2024 | Airsupra, Farxiga, Lokelma |
| Amgen INC. | $322.25 | 2021-2025 | Otezla, Repatha, Repatha |
| Medtronic, INC. | $287.36 | 2021-2024 | Corevalve Evolut R |
| Amarin Pharma, INC. | $281.93 | 2021-2022 | |
| Astellas Pharma US INC | $276.01 | 2023-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $215.08 | 2021-2022 | |
| Exact Sciences Corporation | $211.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $209.36 | 2021-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $171.98 | 2022-2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Brewer-Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.